Application of new cholesterol guidelines to a population-based sample.

Area of Science:

• Cardiology
• Public Health
• Pharmacology

Background:

• The 2013 American College of Cardiology and American Heart Association (ACC-AHA) guidelines broadened recommendations for statin therapy in cardiovascular disease prevention.
• Previous guidelines, such as the Third Adult Treatment Panel (ATP III), had different eligibility criteria for statin use.

Purpose of the Study:

• To estimate the number of U.S. adults eligible for statin therapy under the new ACC-AHA guidelines.
• To compare the risk-factor profile of newly eligible individuals with previous guidelines.
• To extrapolate these findings to the U.S. adult population aged 40-75 years.

Main Methods:

• Utilized data from the National Health and Nutrition Examination Surveys (2005-2010).
• Calculated the number of eligible persons based on ACC-AHA guidelines versus ATP III guidelines.
• Extrapolated findings to an estimated 115.4 million U.S. adults (40-75 years).

Main Results:

• The new ACC-AHA guidelines would increase statin eligibility from 43.2 million (37.5%) to 56.0 million (48.6%) adults.
• The majority of the increase (10.4 million) is among adults without pre-existing cardiovascular disease.
• Eligibility significantly increases for older adults (60-75 years) without cardiovascular disease, particularly men, driven by 10-year cardiovascular event risk assessment.

Conclusions:

• The ACC-AHA cholesterol guidelines substantially increase the number of adults eligible for statin therapy by 12.8 million.
• This expansion primarily affects older adults without cardiovascular disease.
• The updated guidelines enhance sensitivity for identifying individuals who would benefit from statin therapy but may decrease specificity.